ClinicalTrials.gg
Active, not recruitingNCT02375620Updated May 25, 2025

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

A Phase 2 interventional study of PEG-somatropin in Short Stature Children Born Small for Gestational Age (SGA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Active, not recruiting at 9 sites in China. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
3 Years to 7 Years
Sex
All
01

Study summary

The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection.

This is a multicenter, randomized, open-label, dose-response trial, including a 52-week main phase and an ongoing safety extension phase continuing until reaching near-adult height (NAH) in China. Ninety-six growth hormone (GH)-treatment-naïve, non-GH-deficient, prepubertal short children born SGA were randomized in a 1:1 ration to receive weekly subcutaneous administration of Jintrolong 0.1 mg/kg/week or 0.2 mg/kg/week for 52 weeks. Children who completed the 52- week main phase proceeded to the extension phase, while Jintrolong was administered at an initial dose of 0.2 mg/kg/week. Dose adjustments based on annualized height velocity (AHV) and insulin-like growth factor I (IGF-I) response, were made up to a maximum of 0.4 mg/kg/week until achieved NAH or the patient's voluntary discontinuation.

02

Conditions studied

  • Short Stature Children Born Small for Gestational Age (SGA)
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patients are diagnosed as being clinically full term small for gestational age infant.
  • Girl are 3-6 years old, boys are 3-7 years old.
  • Be in preadolescence (Tanner stage 1).
  • The child did not achieve catch-up growth when he/she entered the group (the definition of catch-up growth is that the height is higher the third percentile with the same age and gender) (Appendix 2 and 3).
  • The height of child is shorter than -2SDS of the median of normal children with the same age and gender when he/she entered the group (the mean height and height standard deviation of normal children with the same age and gender of normal children regard the height data in the physical development investigation data of children aged 0-18 in 9 cities of China (2005) as standard [13], Appendix 4 and 5).
  • Within a year before entering the group, after any growth hormone stimulation test, the peak concentration of growth hormone in serum>10 µg/L.
  • Bone age≤ the actual age+1.
  • The function of glucose regulation is normal: fasting blood glucose \< 5.6mmol/L.
  • Birth gestational age ≥ 37 weeks.
  • The subjects and their guardians sign the (if the subjects is lack of ability for signing the informed consent, his legal guardian can write the subjects name instead).
  • All experimental drug groups completed the main phase (52 weeks) of Phase II clinical trials, and the participants with complete follow-up records can enter the extension phase, provided that the continuous cessation of the use of pegylated recombinant human growth hormone injection lasts ≤ 8 weeks after the end of the first phase treatment and before the start of the extended study.
  • Only when the subjects and their guardians are fully informed, express their willingness, and are able to cooperate in completing the treatment, follow-up, and various tests of the extension phase study, and have signed a written informed consent form, can they enter the extension phase trial.

Exclusion criteria

Exclusion Criteria:

  • People with abnormal liver or kidney function (> 2 times the value, Cr> the upper limit of normal value).
  • Patients are positive for core antigen (HBc), hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg).
  • People with known highly allergic constitution or allergy to the drug or the of the study.
  • People with diabetes, severe cardiopulmonary, hematological system and malignant tumors diseases or general infection, immune deficiency and patients with mental disease.
  • Other abnormal growth and development, such as Turner syndrome, Laron syndrome, growth hormone receptor deficiency.
  • Potential tumor patients (family history).
  • Patients who used growth hormone for treatment.
  • Subjects took part in other clinical trial study within 3 months.
  • Patients used other hormonal for treatment within 3 months (such as sex hormone, and etc., treat for more than a month) and received the drug treatment which may interfere with the secretion of GH or GH function (oxandrolone, growth hormone releasing hormone and etc.);
  • Other conditions which in the opinion of the investigator preclude enrollment into the study.
  • Subjects who have used the following medications within 2 months prior to entering the expansion phase of the trial:
    1. Aromatase inhibitors (including but not limited to letrozole, anastrozole) used continuously for 1 month;
    1. Gonadotropin-releasing hormone analogs (including but not limited to triptorelin, leuprolide, goserelin) used continuously for 1 month;
    1. Sex hormones (including but not limited to any type of estrogen, progestin, and androgen) used continuously for 1 month;
    1. Anabolic steroids (including but not limited to oxymetholone, danazol, stanozolol) used continuously for ≥ 1 month;
    1. Oral or intravenous corticosteroids used for 1 month.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    PEG-somatropin: Low dose

    0.1 mg/(kg.w), once per week for 52 weeks.

    Biological: PEG-somatropin

  • Experimental
    PEG-somatropin: High dose

    0.2 mg/(kg.w), once per week for 52 weeks.

    Biological: PEG-somatropin

  • Experimental
    Children who completed the 52- week main phase proceeded to the extension phase

    Dose adjustments based on annualized height velocity (AHV; cm/year) and insulin-like growth factor I (IGF-I) response, were made up to a maximum of 0.4 mg/kg/week until achieved NAH or the patient's voluntary discontinuation.

    Biological: PEG-somatropin

Interventions

06

What researchers measure

Primary outcomes

  1. The change in height standard deviation scores (HT SDS) of the chronological age from baseline.

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

Secondary outcomes

  1. Annualized Height Velocity

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

  2. The change of height from baseline

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

  3. Bone maturity (bone age/ chronological age , △BA/△CA )

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

  4. The change of IGF-1 standard deviation scores(IGF-1 SDS) from baseline

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

  5. The change of mole ratio of IGF-1/IGFBP-3 from baseline

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

  6. The change of BMI standard deviation scores(BMI SDS)

    Time frame: The main phase is at 52 weeks and the extension phase is at every 52 weeks up to study completion.

07

Study locations

9 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Dec 2023, 103 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2015
First posted
Mar 2, 2015
StartActual
Apr 23, 2015
Primary completionActual
Dec 12, 2023
CompletionEst.
Dec 2025
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02375620
Collaborators
Shanxi Provincial Maternity and Children's Hospital, Children's Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, The First Hospital of Jilin University, Hunan Children's Hospital, Tongji Hospital, Affiliated Hospital of Jiangnan University, Jiangxi Province Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics
Responsible party
Sponsor
First posted
Mar 2, 2015
Start date
Apr 23, 2015
Primary completion
Dec 12, 2023
Completion
Dec 2025 (estimated)
Last update
May 25, 2025

Study contacts

Xiaoping Luo, Ph.D
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion